The JCVI have advised that children aged 12 to 15 should be invited for a second dose of COVID-19 vaccine at 3 months after their first dose. We are discussing the implications of this advice with the COMCOV3 study Trial Steering Committee, and will share any information regarding the impact of the change with the COMCOV3 participants and their families as soon as possible.
The Oxford Vaccine Group’s Com-Cov vaccine trial is studying the use of different combinations of approved COVID-19 vaccines for the first and second immunisation doses.
This study is being led by the Oxford Vaccine Group (Chief Investigator Associate Professor Matthew Snape), and delivered by a network of trial sites across the UK. The study is funded by the Vaccine Task Force and the National Institute for Health Research (NIHR).
Our researchers are working hard to get the results available to inform UK immunisation policy as quickly as possible. We ask that the media do not continue to contact researchers while this critical work is underway, and to use the media contact form for press enquiries.